Mclaughlinsong3406

One of the methods used to treat coronary artery disease (CAD) is anticoagulant therapy, which involves administering anticoagulants to patients that inhibit the arrangement and actuation of clotting factors. Anticoagulant therapy in patients with CAD must be monitored and evaluated because its greatest side effect is the risk of bleeding. The research aimed to analyze anticoagulants used in therapy for CAD patients and identify potential adverse drug reactions and adverse drug interactions.

This was an observational study which collected data retrospectively at Bhayangkara Hospital Surabaya. Patient data had to meet the requirements for inclusion, which were patients treated for a diagnosis of CAD with anticoagulant therapy and were in conditions with or without complications and comorbid diseases. Data were obtained from 40 patient medical records. The data were then processed descriptively.

Most patients were male (80%) and aged 61-70 years old (37.5%). Fondaparinux was administered to 18 patients at a dose of 1×2.5mg SC. Furthermore, enoxaparin was administered to 15 patients at a dose of 2×60mg SC, and seven patients received warfarin at a dose of 1×2-4mg per oral.

The anticoagulants used in this study were fondaparinux 1×2.5mg SC (45%), enoxaparin 2×60mg SC (37.5%), and warfarin 1×2-4mg PO (17.5%). Side effects of the anticoagulants were absent. However, drug interactions with aspirin, clopidogrel, and allopurinol increased the risk of bleeding.

The anticoagulants used in this study were fondaparinux 1 × 2.5 mg SC (45%), enoxaparin 2 × 60 mg SC (37.5%), and warfarin 1 × 2-4 mg PO (17.5%). Side effects of the anticoagulants were absent. However, drug interactions with aspirin, clopidogrel, and allopurinol increased the risk of bleeding.

Histamine

-methyltransferase (HNMT) is an enzyme that plays a crucial role in the inactivation of histamine in central nervous system, kidneys and bronchi. Inhibition of HNMT is known to have a potential role in treating attention-deficit hyperactivity disorder, memory impairment, mental illness and neurodegenerative illnesses. Therefore, to find potential compounds that could be developed as novel HNMT inhibitors, this study conducted an

study of the secondary metabolites of

L and

.

In this study, we conducted a molecular docking study of 36 secondary metabolites of

L and 26 secondary metabolites of

using an

approach targeting HNMT protein (PDB ID 2AOT) using AutoDockVina software. ABT-199 The prediction of ADMET characteristics was done using the pkCSM Online Tool.

This study obtained one metabolite from

L (longifolene) and seven metabolites from

(+)-beta-atlantone, humulene epoxide, (-)-beta-curcumene, (E)-caryophyllene, germacrone, (R)-(-)-xanthorrhizol, and (-)-beta-caryophyllene epoxide which were predicted to have potential to be developed as HNMT inhibitors.

This study found several secondary metabolites of

L and

which had activity as HNMT inhibitors. This research can likewise be utilized as a basis for further research, both

,

, and clinical trials related to the development of secondary metabolites from

L and

as novel HNMT inhibitor compounds.

This study found several secondary metabolites of N. sativa L and C. xanthorrhiza Roxb which had activity as HNMT inhibitors. This research can likewise be utilized as a basis for further research, both in vitro, in vivo, and clinical trials related to the development of secondary metabolites from N. sativa L and C. xanthorrhiza Roxb as novel HNMT inhibitor compounds.

The high prevalence of HER2-positive breast cancer has become a significant concern in the health sector. The problem is more complex with the side effects of breast cancer drugs currently used. Thymoquinone (TQ), the main bioactive compound in

, has been shown to have anticancer activity. However, it is necessary to modify the structure of the thymoquinone derivatives to improve drug bioavailability. This study uses an

approach to predict pharmacokinetic profile, docking, quantitative structure-properties relationship (QSPR) of new thymoquinone-derived compounds as candidates cytotoxic agent for breast cancer with HER-2 positive.

The prediction of ADMET was using pkCSM online. Molecular docking was used to determine thymoquinone derivatives activity using Molegro Virtual Docker version 5.5 by docking the thymoquinone derivatives to the HER2 receptor targets, PDB ID 3PP0 and QSPR analysis using the IBM SPSS 21 version.

The 35 thymoquinone derivatives showed good physicochemical and absorption properties and not hepatotoxic, so they are suitable for oral drugs. The molecular docking of 35 thymoquinone derivatives against 3PP0 proteins showed better activity than thymoquinone. One of the thymoquinone derivatives, TQ 15, showed the largest negative RS value, meaning that is predicted to have the highest anticancer activity. Based on the QSPR analysis, the essential parameter in determining 35 thymoquinone derivatives activity was the lipophilic and steric parameter.

Based on

test, thymoquinone derivative, TQ 15, had the potential to be further developed as a HER2-positive breast cancer drug.

Based on in silico test, thymoquinone derivative, TQ 15, had the potential to be further developed as a HER2-positive breast cancer drug.

Bone defect is serious condition that is usually caused by traffic accident. Chitosan is a polymer developed as a scaffold to treat bone defect. However, the mechanism by which chitosan can accelerate bone growth in defect area is still unclear. This study aims to identify proteins which are crucial to the osteogenic properties of chitosan monomer using an

study.

Molecular docking was carried out on chitosan monomer, which are d-glucosamine and glucosamine 6-phosphate units against bone morphogenetic protein 2 (BMP-2), fibronectin, fibroblast growth factor (Fgf), and phosphate transporter (PiT) using AutoDock Vina. Ligand preparation was carried out using Chem3D version 15.0.0.106, while protein preparation was performed using AutoDockTools version 1.5.6.

The results showed that glucosamine 6-phosphate had the best binding affinity with fibronectin and PiT, which was-5.7kcalmol

on both proteins, while d-glucosamine had the best binding affinity with PiT (-5.2kcalmol

).

This study suggests that the osteogenic properties of chitosan may be due to the presence of bonds between glucosamine units and fibronectin and/or PiT.